Characteristics of patients newly prescribed a long acting bronchodilator in the US

K. Wurst, S. St. Laurent, H. Muellerova, K. Davis (Research Triangle Park, United States Of America; Uxbridge, United Kingdom)

Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Session: Treatment and adherence to treatment of respiratory disease
Session type: Thematic Poster Session
Number: 965
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Wurst, S. St. Laurent, H. Muellerova, K. Davis (Research Triangle Park, United States Of America; Uxbridge, United Kingdom). Characteristics of patients newly prescribed a long acting bronchodilator in the US. Eur Respir J 2013; 42: Suppl. 57, 965

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The clinical impact of long-acting bronchodilators in newly diagnosed COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Use of long acting bronchodilators and inhaled corticosteroids within 30-days of discharge in older adults hospitalized for AECOPD
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015


Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015


Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Characteristics of patients newly prescribed a long acting bronchodilator in the United Kingdom (UK)
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014

Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014


Differences in adherence to common inhaled medications in COPD
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Prescribing patterns for UK patients commencing first maintenance therapy for COPD
Source: International Congress 2014 – COPD markers
Year: 2014


Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes
Source: International Congress 2014 – Markers
Year: 2014


Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD?
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013